Evidence map›Paper›PMID 25693838›Full record

ArticleThe Journal of pathology2015

Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.

Qian Wang, Rae-Anne Hardie, Andrew J Hoy, Michelle van Geldermalsen, Dadi Gao, Ladan Fazli, Martin C Sadowski, Seher Balaban, Mark Schreuder, Rajini Nagarajah and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed, 1 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

233 citing papers in PubMed, 1 synthesis or guideline pooled it, 325 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2020
    Guideline
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Retraction:Oncotarget · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Implications of Heterotypic Cell Fusion in Cancer.Advances in experimental medicine and biology · 2026
    Review
  13. Article
  14. Translational andrology and urology · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

173 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Qian WangOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
Rae-Anne HardieOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
Andrew J HoyDiscipline of Physiology, Bosch Institute and Charles Perkins Centre, University of Sydney, NSW, Australia.
Michelle van GeldermalsenOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
Dadi GaoSydney Medical School, University of Sydney, NSW, Australia.
Ladan FazliDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Martin C SadowskiAustralian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Australia.
Seher BalabanDiscipline of Physiology, Bosch Institute and Charles Perkins Centre, University of Sydney, NSW, Australia.
Mark SchreuderDiscipline of Physiology, Bosch Institute and Charles Perkins Centre, University of Sydney, NSW, Australia.
Rajini NagarajahOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
Justin J-L WongSydney Medical School, University of Sydney, NSW, Australia.
Cynthia MetierreSydney Medical School, University of Sydney, NSW, Australia.
Natalia PinelloSydney Medical School, University of Sydney, NSW, Australia.
Nicholas J OtteOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
Melanie L LehmanAustralian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Australia.
Martin GleaveDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Colleen C NelsonAustralian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Australia.
Charles G BaileySydney Medical School, University of Sydney, NSW, Australia.
William RitchieSydney Medical School, University of Sydney, NSW, Australia.
John E J RaskoSydney Medical School, University of Sydney, NSW, Australia.
Jeff HolstOrigins of Cancer Laboratory, Centenary Institute, Camperdown, NSW, Australia.
The University of Sydney · AUCentenary Institute · AUQueensland University of Technology · AUUniversity of British Columbia · CAProstate Cancer Foundation of Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for macromolecule production, as well as for anaplerotic reactions fuelling the tricarboxylic acid (TCA) cycle. In this study, we demonstrated that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer patient samples. Using LNCaP and PC-3 prostate cancer cell lines, we showed that chemical or shRNA-mediated inhibition of ASCT2 function in vitro decreases glutamine uptake, cell cycle progression through E2F transcription factors, mTORC1 pathway activation and cell growth. Chemical inhibition also reduces basal oxygen consumption and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2-mediated glutamine uptake. Furthermore, shRNA knockdown of ASCT2 in PC-3 cell xenografts significantly inhibits tumour growth and metastasis in vivo, associated with the down-regulation of E2F cell cycle pathway proteins. In conclusion, ASCT2-mediated glutamine uptake is essential for multiple pathways regulating the cell cycle and cell growth, and is therefore a putative therapeutic target in prostate cancer.

Indexed as

Gene Expression Regulation, NeoplasticAmino Acid Transport System ASCAnimalsBiological TransportCell CycleCell Line, TumorCell ProliferationDown-RegulationFatty AcidsGene Knockdown TechniquesGlutamineHeterograftsHumansMaleMechanistic Target of Rapamycin Complex 1MiceAmino Acid Transport System ASCFatty AcidsGlutamineMechanistic Target of Rapamycin Complex 1Minor Histocompatibility AntigensMultiprotein ComplexesOxygenRNA, Small InterferingSLC1A5 protein, humanTOR Serine-Threonine KinasesASCT2cell cycleglutaminemetabolismprostate cancerSLC1A5

Identifiers

PMID25693838
PMCPMC4973854
OpenAlexW2137785594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.